Correlation Between Fate Therapeutics and Centessa Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fate Therapeutics and Centessa Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fate Therapeutics and Centessa Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fate Therapeutics and Centessa Pharmaceuticals PLC, you can compare the effects of market volatilities on Fate Therapeutics and Centessa Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fate Therapeutics with a short position of Centessa Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fate Therapeutics and Centessa Pharmaceuticals.

Diversification Opportunities for Fate Therapeutics and Centessa Pharmaceuticals

-0.43
  Correlation Coefficient

Very good diversification

The 3 months correlation between Fate and Centessa is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Fate Therapeutics and Centessa Pharmaceuticals PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Centessa Pharmaceuticals and Fate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fate Therapeutics are associated (or correlated) with Centessa Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Centessa Pharmaceuticals has no effect on the direction of Fate Therapeutics i.e., Fate Therapeutics and Centessa Pharmaceuticals go up and down completely randomly.

Pair Corralation between Fate Therapeutics and Centessa Pharmaceuticals

Given the investment horizon of 90 days Fate Therapeutics is expected to under-perform the Centessa Pharmaceuticals. In addition to that, Fate Therapeutics is 1.94 times more volatile than Centessa Pharmaceuticals PLC. It trades about -0.15 of its total potential returns per unit of risk. Centessa Pharmaceuticals PLC is currently generating about 0.06 per unit of volatility. If you would invest  1,557  in Centessa Pharmaceuticals PLC on September 23, 2024 and sell it today you would earn a total of  159.00  from holding Centessa Pharmaceuticals PLC or generate 10.21% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Fate Therapeutics  vs.  Centessa Pharmaceuticals PLC

 Performance 
       Timeline  
Fate Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Centessa Pharmaceuticals 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Centessa Pharmaceuticals PLC are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Centessa Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point.

Fate Therapeutics and Centessa Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fate Therapeutics and Centessa Pharmaceuticals

The main advantage of trading using opposite Fate Therapeutics and Centessa Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fate Therapeutics position performs unexpectedly, Centessa Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Centessa Pharmaceuticals will offset losses from the drop in Centessa Pharmaceuticals' long position.
The idea behind Fate Therapeutics and Centessa Pharmaceuticals PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance